Consequently, the efficiency of ketone body production is critically dependent on adequate L-carnitine availability (Figure 2)
Eligibility typically requires a BMI of 30 kg/m or higher, or BMI of 27 kg/m or higher with weight-related comorbidities such as hypertension, dyslipidemia, or obstructive sleep apnea
The Journal of pharmacy technology : jPT: official publication of the Association of Pharmacy Technicians, 41(1), 2231
GLP-1 receptor agonist medications mimic these effects pharmacologically, producing several mechanisms that contribute to weight loss: Reduced appetite and food intake by activating satiety signaling in the brain, these medications meaningfully reduce hunger and food preoccupation for most patients Slower gastric emptying food remains in the stomach longer, prolonging the feeling of fullness after meals Improved insulin sensitivity better glucose regulation reduces post-meal energy crashes that often drive cravings Lower preference for high-calorie foods many patients report shifts in food preferences toward lighter, less calorie-dense options Tirzepatide adds a second mechanism by also activating GIP (glucose-dependent insulinotropic polypeptide) receptors, which is believed to contribute to its greater weight loss effect compared to semaglutide alone
Another component of nutritional management is to improve safety in patients with PBH by adequate correction of hypoglycemic events
discuss risk and symptoms with a clinician
